Inhibition of Human Tyrosyl-DNA Phosphodiesterase by Aminoglycoside Antibiotics and Ribosome Inhibitors

DNA topoisomerase I (Top1) is the target of camptothecin, and novel Top1 inhibitors are in development as anticancer agents. Top1 inhibitors damage DNA by trapping covalent complexes between the Top1 catalytic tyrosine and the 3′-end of the broken DNA. Tyrosyl-DNA phosphodiesterase (Tdp1) can repair Top1-DNA covalent complexes by hydrolyzing the tyrosyl-DNA bond. Inhibiting Tdp1 has the potential to enhance the anticancer activity of Top1 inhibitors (http://discover.nci.nih.gov/pommier/pommier.htm) and to act as antiproliferative agents. In the present study, we report that neomycin inhibits Tdp1 more effectively than the related aminoglycosides paromomycin and lividomycin A. Inhibition of Tdp1 by neomycin is observed both with single- and double-stranded substrates but is slightly stronger with duplex DNA, which is different from aclarubicin, which only inhibits Tdp1 with the double-stranded substrate. Inhibition by neomycin can be overcome with excess Tdp1 and is greatest at low pH. To our knowledge, aminoglycoside antibiotics and the ribosome inhibitors thiostrepton, clindamycin-2-phosphate, and puromycin are the first reported pharmacological Tdp1 inhibitors.

[1]  P. Cerutti.  Prooxidant states and tumor promotion. , 1985, Science.

[2]  J. Champoux,et al.  The crystal structure of human tyrosyl-DNA phosphodiesterase, Tdp1. , 2002, Structure.

[3]  H. Paulson,et al.  Breaks in Coordination: DNA Repair in Inherited Ataxia , 2005, Neuron.

[4]  L. Kotra,et al.  Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[5]  J. Champoux.  DNA topoisomerases: structure, function, and mechanism. , 2001, Annual review of biochemistry.

[6]  Y. Pommier,et al.  Repair of topoisomerase I-mediated DNA damage. , 2006, Progress in nucleic acid research and molecular biology.

[7]  Y. Pommier,et al.  Processing of nucleopeptides mimicking the topoisomerase I-DNA covalent complex by tyrosyl-DNA phosphodiesterase. , 2002, Nucleic acids research.

[8]  J. Pouliot,et al.  Yeast gene for a Tyr-DNA phosphodiesterase that repairs topoisomerase I complexes. , 1999, Science.

[9]  J. Champoux,et al.  Explorations of peptide and oligonucleotide binding sites of tyrosyl-DNA phosphodiesterase using vanadate complexes. , 2004, Journal of medicinal chemistry.

[10]  A. Burgin,et al.  Analysis of human tyrosyl-DNA phosphodiesterase I catalytic residues. , 2004, Journal of molecular biology.

[11]  A. Burgin,et al.  Substrate Specificity of Tyrosyl-DNA Phosphodiesterase I (Tdp1)* , 2005, Journal of Biological Chemistry.

[12]  J. Lupski,et al.  Defective DNA single-strand break repair in spinocerebellar ataxia with axonal neuropathy-1 , 2005, Nature.

[13]  P. D'Arpa,et al.  Ubiquitin-dependent Destruction of Topoisomerase I Is Stimulated by the Antitumor Drug Camptothecin* , 1997, The Journal of Biological Chemistry.

[14]  Y. Pommier,et al.  Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy. , 2003, Current topics in medicinal chemistry.

[15]  R. Schroeder,et al.  Modulation of RNA function by aminoglycoside antibiotics , 2000, The EMBO journal.

[16]  J. Champoux,et al.  SCAN1 mutant Tdp1 accumulates the enzyme–DNA intermediate and causes camptothecin hypersensitivity , 2005, The EMBO journal.

[17]  Y. Pommier,et al.  Interfacial inhibitors of protein-nucleic acid interactions. , 2005, Current medicinal chemistry. Anti-cancer agents.

[18]  K. Kohn,et al.  Repair of and checkpoint response to topoisomerase I-mediated DNA damage. , 2003, Mutation research.

[19]  Chunyan Liu,et al.  Repair of topoisomerase I covalent complexes in the absence of the tyrosyl-DNA phosphodiesterase Tdp1 , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[20]  Huili Chen,et al.  Effects of phosphatidylinositol 4,5-bisphosphate and neomycin on phospholipase D: Kinetic studies , 1999, Molecular and Cellular Biochemistry.

[21]  J. Lupski,et al.  Deficiency in 3′-phosphoglycolate processing in human cells with a hereditary mutation in tyrosyl-DNA phosphodiesterase (TDP1) , 2005, Nucleic acids research.

[22]  J. Champoux,et al.  Crystal structure of a transition state mimic for Tdp1 assembled from vanadate, DNA, and a topoisomerase I-derived peptide. , 2003, Chemistry & biology.

[23]  T. E. Wilson,et al.  Yeast Tdp1 and Rad1-Rad10 function as redundant pathways for repairing Top1 replicative damage , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[24]  Y. Pommier,et al.  Topoisomerase I-mediated DNA damage. , 2001, Advances in cancer research.

[25]  J. Champoux,et al.  Insights into substrate binding and catalytic mechanism of human tyrosyl-DNA phosphodiesterase (Tdp1) from vanadate and tungstate-inhibited structures. , 2002, Journal of molecular biology.

[26]  Morten O. Christensen,et al.  TDP1 Overexpression in Human Cells Counteracts DNA Damage Mediated by Topoisomerases I and II* , 2004, Journal of Biological Chemistry.

[27]  J. Champoux,et al.  The tyrosyl-DNA phosphodiesterase Tdp1 is a member of the phospholipase D superfamily , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[28]  JAMES C. Wang,et al.  Cellular roles of DNA topoisomerases: a molecular perspective , 2002, Nature Reviews Molecular Cell Biology.

[29]  V. Ramakrishnan,et al.  Recognition of Cognate Transfer RNA by the 30S Ribosomal Subunit , 2001, Science.

[30]  L. Povirk,et al.  Conversion of Phosphoglycolate to Phosphate Termini on 3′ Overhangs of DNA Double Strand Breaks by the Human Tyrosyl-DNA Phosphodiesterase hTdp1* , 2002, The Journal of Biological Chemistry.

[31]  J. Lupski,et al.  Mutation of TDP1, encoding a topoisomerase I–dependent DNA damage repair enzyme, in spinocerebellar ataxia with axonal neuropathy , 2002, Nature Genetics.

[32]  Y. Pommier,et al.  Interfacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. , 2005, Trends in pharmacological sciences.

[33]  Y. Pommier,et al.  Apoptotic Topoisomerase I-DNA Complexes Induced by Oxygen Radicals and Mitochondrial Dysfunction , 2004, Cell cycle.

[34]  R. Hertzberg,et al.  Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. , 1985, The Journal of biological chemistry.

[35]  A. Burgin,et al.  A eukaryotic enzyme that can disjoin dead-end covalent complexes between DNA and type I topoisomerases. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[36]  James Pustejovsky,et al.  Biomedical term mapping databases , 2004, Nucleic Acids Res..

[37]  J. Pouliot,et al.  Pathways for repair of topoisomerase I covalent complexes in Saccharomyces cerevisiae , 2001, Genes to cells : devoted to molecular & cellular mechanisms.

[38]  Thomas A Steitz,et al.  The structural basis of large ribosomal subunit function. , 2002, Annual review of biochemistry.

[39]  Yves Pommier,et al.  Association of XRCC1 and tyrosyl DNA phosphodiesterase (Tdp1) for the repair of topoisomerase I-mediated DNA lesions. , 2003, DNA repair.

[40]  J. Champoux,et al.  Human Tdp1 Cleaves a Broad Spectrum of Substrates, Including Phosphoamide Linkages* , 2005, Journal of Biological Chemistry.

[41]  Y. Pommier,et al.  Mechanism of action of eukaryotic DNA topoisomerase I and drugs targeted to the enzyme. , 1998, Biochimica et biophysica acta.